A Breakthrough: Macrophage-Directed Cancer Immunotherapy
Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression of tumors. Specifically, M2/repair-type macrophages predominate in human cancers and produce growth-promoting molecules that actively stimulate tumor...
Saved in:
| Published in | Cancer research (Chicago, Ill.) Vol. 76; no. 3; pp. 513 - 516 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.02.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression of tumors. Specifically, M2/repair-type macrophages predominate in human cancers and produce growth-promoting molecules that actively stimulate tumor growth in much the same way they help wounds heal. However, modulating M2/repair-type macrophages to M1/kill-type can slow or stop cancer growth. The effects involve direct activity of M1 kill-type as well as the ability of M1-type macrophages to stimulate Th1-type cytotoxic T cells and other effector cells. Macrophage responses can also predict cancer susceptibility; individuals with a high M1/kill to M2/repair ratio are less prone. That macrophages/innate immunity can be modulated to play a central role in directly or indirectly combating cancer is a breakthrough that seems likely to finally make successful immunotherapy of cancer a reality. |
|---|---|
| AbstractList | Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression of tumors. Specifically, M2/repair-type macrophages predominate in human cancers and produce growth-promoting molecules that actively stimulate tumor growth in much the same way they help wounds heal. However, modulating M2/repair-type macrophages to M1/kill-type can slow or stop cancer growth. The effects involve direct activity of M1 kill-type as well as the ability of M1-type macrophages to stimulate Th1-type cytotoxic T cells and other effector cells. Macrophage responses can also predict cancer susceptibility; individuals with a high M1/kill to M2/repair ratio are less prone. That macrophages/innate immunity can be modulated to play a central role in directly or indirectly combating cancer is a breakthrough that seems likely to finally make successful immunotherapy of cancer a reality. Abstract Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression of tumors. Specifically, M2/repair-type macrophages predominate in human cancers and produce growth-promoting molecules that actively stimulate tumor growth in much the same way they help wounds heal. However, modulating M2/repair-type macrophages to M1/kill-type can slow or stop cancer growth. The effects involve direct activity of M1 kill-type as well as the ability of M1-type macrophages to stimulate Th1-type cytotoxic T cells and other effector cells. Macrophage responses can also predict cancer susceptibility; individuals with a high M1/kill to M2/repair ratio are less prone. That macrophages/innate immunity can be modulated to play a central role in directly or indirectly combating cancer is a breakthrough that seems likely to finally make successful immunotherapy of cancer a reality. Cancer Res; 76(3); 513–6. ©2016 AACR. |
| Author | Mills, Charles D Lenz, Laurel L Harris, Robert A |
| AuthorAffiliation | 3 Applied Immunology & Immunotherapy, Dept. Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden 1 BioMedical Consultants, Marine on St. Croix, MN 55047 2 Immunology and Microbiology Department, University of Colorado School of Medicine, Aurora CO 80045 |
| AuthorAffiliation_xml | – name: 3 Applied Immunology & Immunotherapy, Dept. Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden – name: 1 BioMedical Consultants, Marine on St. Croix, MN 55047 – name: 2 Immunology and Microbiology Department, University of Colorado School of Medicine, Aurora CO 80045 |
| Author_xml | – sequence: 1 givenname: Charles D surname: Mills fullname: Mills, Charles D email: mills002@umn.edu organization: BioMedical Consultants, Marine on St. Croix, Minnesota. mills002@umn.edu – sequence: 2 givenname: Laurel L surname: Lenz fullname: Lenz, Laurel L organization: Immunology and Microbiology Department, University of Colorado School of Medicine, Aurora, Colorado – sequence: 3 givenname: Robert A surname: Harris fullname: Harris, Robert A organization: Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26772756$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:132848498$$DView record from Swedish Publication Index |
| BookMark | eNpVkc1u2zAQhInCQWK7eYQWPvYil38rUj0UcNy0CZCkl-RMUNLKUm2JLim1yNuHgh0jORBLLmeGC34zMulch4R8YnTJGOivlFKdgFR8WdguYZAwJdQHMmUgdKKkhAmZnjQXZBbCn3gERuGcXPBUKa4gnRK9Wlx5tNu-9m7Y1N8W97bwbl_bDSY_Go9Fj-VibbsC_eK2bYfO9TV6u3_-SM4quwt4eaxz8vTz-nF9k9z9_nW7Xt0lRSpYn-SYZyhFXmZQ5TITFXCsJECe0ZRBmmaZElRoyaIMUlFyXnFVKGllCVJUQsxJdsgN_3E_5Gbvm9b6Z-NsE_euNMf-thmXCWiY4Fpqmeno_X7wRkGLZYFd7-3ufcS7m66pzcb9M1IJTeNcc_LlGODd3wFDb9omFLjb2Q7dEAxTKReSS2BRCgdp_L4QPFanZxg1IzEz0jAjDbNePRgGZiQWfZ_fznhyvSISL6WTlHs |
| CitedBy_id | crossref_primary_10_1126_sciadv_aaz6579 crossref_primary_10_12677_ACM_2022_125676 crossref_primary_10_1002_adhm_202101844 crossref_primary_10_1158_1078_0432_CCR_16_0460 crossref_primary_10_1016_j_apsb_2023_03_020 crossref_primary_10_1155_2023_6665452 crossref_primary_10_1155_2016_9720912 crossref_primary_10_1016_j_cllc_2020_06_016 crossref_primary_10_2217_nnm_2017_0324 crossref_primary_10_1124_jpet_118_254979 crossref_primary_10_1038_s41746_020_0275_x crossref_primary_10_3390_molecules28237784 crossref_primary_10_18632_oncotarget_26892 crossref_primary_10_1021_acs_chemrev_8b00271 crossref_primary_10_1158_0008_5472_CAN_17_2465 crossref_primary_10_1002_cncr_32016 crossref_primary_10_1186_s12967_017_1139_2 crossref_primary_10_3390_cancers13153885 crossref_primary_10_1039_D1CC05999H crossref_primary_10_1016_j_cej_2021_133847 crossref_primary_10_1016_j_diff_2023_01_001 crossref_primary_10_3390_medicina56010015 crossref_primary_10_3389_fgene_2022_1010440 crossref_primary_10_3389_fphar_2020_577571 crossref_primary_10_3390_vaccines9091009 crossref_primary_10_1002_anie_202004206 crossref_primary_10_1016_j_biopha_2023_115104 crossref_primary_10_1016_j_jdermsci_2016_05_015 crossref_primary_10_1016_j_ejphar_2022_175206 crossref_primary_10_1002_path_4763 crossref_primary_10_1007_s00011_022_01550_w crossref_primary_10_1039_D1NR03201A crossref_primary_10_1002_adma_202207787 crossref_primary_10_1039_D3MH00831B crossref_primary_10_1172_jci_insight_89140 crossref_primary_10_3389_fonc_2018_00315 crossref_primary_10_1016_j_addr_2022_114136 crossref_primary_10_18632_aging_204868 crossref_primary_10_1016_j_envres_2023_116748 crossref_primary_10_1039_D2TB00583B crossref_primary_10_18632_oncotarget_11276 crossref_primary_10_2147_IJGM_S352851 crossref_primary_10_1186_s12967_021_02870_x crossref_primary_10_3389_fphar_2023_1249145 crossref_primary_10_3390_nu15194181 crossref_primary_10_1038_s41467_021_24610_x crossref_primary_10_3390_ph16010023 crossref_primary_10_3389_fimmu_2023_1229560 crossref_primary_10_1039_C7SC04853J crossref_primary_10_3390_nano11123227 crossref_primary_10_1038_s41423_023_01047_4 crossref_primary_10_1007_s00262_020_02504_z crossref_primary_10_1088_2053_1591_aaf2d2 crossref_primary_10_52396_JUSTC_2022_0185 crossref_primary_10_1016_j_bbrc_2024_150339 crossref_primary_10_1088_1748_605X_abd2c8 crossref_primary_10_3390_cancers15020394 crossref_primary_10_1016_j_semcancer_2018_04_003 crossref_primary_10_1016_j_lers_2018_01_001 crossref_primary_10_1002_ijc_30643 crossref_primary_10_1016_j_semcancer_2022_08_007 crossref_primary_10_3390_ijms19051477 crossref_primary_10_1186_s13058_021_01481_0 crossref_primary_10_1039_D2NR04693H crossref_primary_10_3389_fimmu_2023_1237711 crossref_primary_10_1002_ctm2_478 crossref_primary_10_1002_ptr_7545 crossref_primary_10_1007_s00005_017_0497_z crossref_primary_10_1158_0008_5472_CAN_21_3503 crossref_primary_10_3390_cancers14092220 crossref_primary_10_1155_2023_7133726 crossref_primary_10_1021_acs_jmedchem_9b00946 crossref_primary_10_1007_s00281_023_00988_2 crossref_primary_10_1007_s00795_018_0201_3 crossref_primary_10_1016_j_redox_2022_102452 crossref_primary_10_1186_s12967_019_1883_6 crossref_primary_10_1371_journal_pone_0193640 crossref_primary_10_1080_14712598_2017_1256388 crossref_primary_10_1158_0008_5472_CAN_16_1201 crossref_primary_10_1111_all_13119 crossref_primary_10_1158_1535_7163_MCT_23_0215 crossref_primary_10_1016_j_xcrm_2022_100604 crossref_primary_10_1021_acsami_2c00707 crossref_primary_10_1172_JCI97642 crossref_primary_10_3389_fimmu_2023_1066402 crossref_primary_10_1080_07357907_2019_1582848 crossref_primary_10_7717_peerj_8383 crossref_primary_10_1002_wnan_1632 crossref_primary_10_1002_adma_202204765 crossref_primary_10_1007_s12272_022_01389_z crossref_primary_10_1016_j_tranon_2024_101942 crossref_primary_10_1021_jacs_8b10904 crossref_primary_10_1016_j_apsb_2017_09_005 crossref_primary_10_1002_advs_201801847 crossref_primary_10_3389_fonc_2020_614468 crossref_primary_10_1038_s41598_022_12301_6 crossref_primary_10_1016_j_ejps_2020_105360 crossref_primary_10_1016_j_yexcr_2024_114037 crossref_primary_10_18632_oncotarget_27569 crossref_primary_10_1007_s00262_017_2011_1 crossref_primary_10_1038_s41598_024_58899_7 crossref_primary_10_1189_jlb_4MR1116_479R crossref_primary_10_2217_fon_2022_0156 crossref_primary_10_1002_adma_202000648 crossref_primary_10_1016_j_jconrel_2023_12_007 crossref_primary_10_1038_s41598_019_42237_3 crossref_primary_10_1080_2162402X_2019_1568162 crossref_primary_10_1186_s12967_023_04709_z crossref_primary_10_3389_fonc_2021_704397 crossref_primary_10_1038_s41467_019_10354_2 crossref_primary_10_3389_fphar_2019_01371 crossref_primary_10_1038_s41598_020_77800_w crossref_primary_10_1016_j_addr_2020_06_021 crossref_primary_10_1158_2326_6066_CIR_22_0218 crossref_primary_10_2147_OTT_S273527 crossref_primary_10_3389_fimmu_2023_1279591 crossref_primary_10_3389_fcell_2022_803947 crossref_primary_10_1016_j_omto_2021_07_002 crossref_primary_10_3724_abbs_2023254 crossref_primary_10_7554_eLife_81114 crossref_primary_10_1142_S0192415X2450023X crossref_primary_10_1186_s12964_021_00705_2 crossref_primary_10_1007_s00795_017_0174_7 crossref_primary_10_1016_j_tem_2021_07_001 crossref_primary_10_1016_j_matdes_2020_109388 crossref_primary_10_1371_journal_pone_0191012 crossref_primary_10_1038_s41598_019_47833_x crossref_primary_10_3389_fimmu_2018_02925 crossref_primary_10_31491_APT_2022_09_093 crossref_primary_10_1038_s41467_019_11719_3 crossref_primary_10_1039_C6NR09895A crossref_primary_10_1002_kjm2_12405 crossref_primary_10_3389_fonc_2021_636479 crossref_primary_10_3390_ijms20061461 crossref_primary_10_1093_jpp_rgaa020 crossref_primary_10_18632_aging_203489 crossref_primary_10_1073_pnas_1611380113 crossref_primary_10_1038_s41467_020_20723_x crossref_primary_10_1007_s12195_020_00652_x crossref_primary_10_1016_j_lfs_2022_120572 crossref_primary_10_1002_nano_202200043 crossref_primary_10_1007_s00262_017_2065_0 crossref_primary_10_1016_j_drup_2023_101041 crossref_primary_10_3960_jslrt_17032 crossref_primary_10_3390_ijms24044026 crossref_primary_10_1111_sji_13140 crossref_primary_10_1016_j_jconrel_2020_02_011 crossref_primary_10_2217_fon_2021_0110 crossref_primary_10_3389_fonc_2022_922899 crossref_primary_10_1038_s41419_018_0876_3 crossref_primary_10_1016_j_addr_2021_114033 crossref_primary_10_1172_jci_insight_157285 crossref_primary_10_1016_j_ymthe_2016_11_006 crossref_primary_10_3389_fonc_2022_945518 crossref_primary_10_3390_ijms222011021 crossref_primary_10_1007_s00262_020_02511_0 crossref_primary_10_1016_j_cellimm_2023_104731 crossref_primary_10_1016_j_canlet_2019_03_032 crossref_primary_10_1038_s41392_021_00506_6 crossref_primary_10_1093_jrr_rrab037 crossref_primary_10_1016_j_ejca_2017_08_026 crossref_primary_10_1038_s41420_023_01621_9 crossref_primary_10_1021_acsnano_8b02446 crossref_primary_10_1111_cas_15751 crossref_primary_10_3389_fbioe_2021_784612 crossref_primary_10_1021_acsabm_0c00368 crossref_primary_10_3389_fimmu_2017_01479 crossref_primary_10_1038_s41388_017_0115_x crossref_primary_10_1186_s12943_019_1047_6 crossref_primary_10_1002_ijc_30489 crossref_primary_10_1158_1078_0432_CCR_19_3840 crossref_primary_10_1016_j_ebiom_2021_103578 crossref_primary_10_3389_fgene_2021_646818 crossref_primary_10_1002_advs_201900037 crossref_primary_10_1016_j_semcancer_2019_12_011 crossref_primary_10_1186_s12885_019_6419_1 crossref_primary_10_1096_fj_201900799RR crossref_primary_10_3390_cancers14205081 crossref_primary_10_1002_ange_202004206 crossref_primary_10_1186_s12916_022_02574_z crossref_primary_10_1002_stem_2596 crossref_primary_10_1038_s41575_018_0005_x crossref_primary_10_3389_fimmu_2022_998653 crossref_primary_10_1007_s00262_022_03300_7 crossref_primary_10_1186_s12876_020_01520_8 crossref_primary_10_1016_j_biopha_2023_114469 crossref_primary_10_33667_2078_5631_2021_10_47_52 crossref_primary_10_1007_s12029_021_00725_8 crossref_primary_10_1021_acsmacrolett_9b00046 crossref_primary_10_1080_13543784_2022_2008354 crossref_primary_10_1080_21645515_2023_2219191 crossref_primary_10_1021_acsnano_2c03348 crossref_primary_10_1158_0008_5472_CAN_20_2017 crossref_primary_10_1002_ange_202308413 crossref_primary_10_1186_s40425_018_0363_5 crossref_primary_10_1038_srep35855 crossref_primary_10_1080_21655979_2021_1985857 crossref_primary_10_33590_emj_10311794 crossref_primary_10_3892_ol_2018_7742 crossref_primary_10_4049_jimmunol_1701135 crossref_primary_10_3389_fimmu_2019_01998 crossref_primary_10_1172_JCI131335 crossref_primary_10_1080_2162402X_2017_1309487 crossref_primary_10_32604_oncologie_2022_024898 crossref_primary_10_3390_cancers11122002 crossref_primary_10_1002_adma_202103497 crossref_primary_10_1158_0008_5472_CAN_17_2011 crossref_primary_10_1002_anie_202308413 crossref_primary_10_1016_j_jconrel_2018_11_029 crossref_primary_10_1186_s12920_021_01010_0 crossref_primary_10_3389_fmicb_2021_632505 crossref_primary_10_1016_j_canlet_2022_01_004 crossref_primary_10_1002_clt2_12133 crossref_primary_10_2174_1874357901711010015 crossref_primary_10_1007_s10238_023_01157_3 crossref_primary_10_1371_journal_pone_0243807 crossref_primary_10_3390_ijms23094797 crossref_primary_10_1158_1078_0432_CCR_17_0483 crossref_primary_10_3389_fcell_2021_707073 crossref_primary_10_3233_BLC_180175 crossref_primary_10_3389_fmolb_2021_789703 crossref_primary_10_1016_j_ijbiomac_2016_10_112 crossref_primary_10_1093_cei_uxad080 crossref_primary_10_3389_fcell_2022_901207 crossref_primary_10_1155_2022_2606928 crossref_primary_10_1002_adhm_202100090 crossref_primary_10_3389_fgene_2020_01002 crossref_primary_10_1016_j_biomaterials_2020_120159 crossref_primary_10_3390_cancers15153972 crossref_primary_10_1016_j_iotech_2020_07_001 crossref_primary_10_1016_j_biopha_2019_109105 crossref_primary_10_1016_j_it_2019_02_003 crossref_primary_10_1016_j_nantod_2022_101670 crossref_primary_10_1038_s42003_024_05853_y crossref_primary_10_1002_adbi_201800236 crossref_primary_10_1186_s12876_023_02689_4 crossref_primary_10_3389_fcell_2021_760800 crossref_primary_10_1172_JCI92466 |
| Cites_doi | 10.4049/jimmunol.138.2.550 10.3389/fimmu.2015.00212 10.4049/jimmunol.149.8.2709 10.1615/CritRevImmunol.v21.i5.10 10.1158/0008-5472.CAN-14-2819 10.1159/000380910 10.1084/jem.138.5.1213 10.1126/science.aaa4967 10.1016/j.dci.2010.05.011 10.4049/jimmunol.164.12.6166 10.1084/jem.20112738 10.1615/CritRevImmunol.v32.i6.10 10.1189/jlb.0211094 10.1016/j.ccell.2015.02.015 10.4049/jimmunol.144.10.3877 10.1126/science.183.4124.534 10.1126/science.176.4031.170 10.1084/jem.120.1.105 10.1084/jem.157.5.1448 10.1126/science.1198443 10.1084/jem.169.3.1021 10.1016/j.immuni.2014.06.010 10.1038/nri2784 10.1159/000364945 10.1038/41131 |
| ContentType | Journal Article |
| Copyright | 2016 American Association for Cancer Research. |
| Copyright_xml | – notice: 2016 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1158/0008-5472.can-15-1737 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7445 |
| EndPage | 516 |
| ExternalDocumentID | oai_prod_swepub_kib_ki_se_132848498 10_1158_0008_5472_CAN_15_1737 26772756 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R33 AI102264 – fundername: NIAID NIH HHS grantid: R01 AI065638 |
| GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 476 53G 5GY 5RE 5VS 6J9 ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 EBS ECM EIF EJD F5P FRP GX1 IH2 KQ8 L7B LSO NPM OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ ZA5 AAYXX CITATION H13 7X8 5PM .55 .GJ 3O- 8WZ A6W AAJMC ADTPV AFFNX AI. AOWAS C1A D0S D8T J5H MVM OHT UDS VH1 WHG X7M XJT ZCG ZGI ZZAVC |
| ID | FETCH-LOGICAL-c631t-beb9e43bd95fb493f52ef455b9061566997303841b9e563d22f27c74a4d543f33 |
| ISSN | 0008-5472 1538-7445 |
| IngestDate | Wed Sep 25 09:05:41 EDT 2024 Tue Sep 17 21:25:51 EDT 2024 Thu Jul 25 11:48:31 EDT 2024 Fri Aug 23 02:33:16 EDT 2024 Thu May 23 23:22:57 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | 2016 American Association for Cancer Research. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c631t-beb9e43bd95fb493f52ef455b9061566997303841b9e563d22f27c74a4d543f33 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | http://kipublications.ki.se/Default.aspx?queryparsed=id:132848498 |
| PMID | 26772756 |
| PQID | 1762342451 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | swepub_primary_oai_prod_swepub_kib_ki_se_132848498 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4738030 proquest_miscellaneous_1762342451 crossref_primary_10_1158_0008_5472_CAN_15_1737 pubmed_primary_26772756 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-02-01 |
| PublicationDateYYYYMMDD | 2016-02-01 |
| PublicationDate_xml | – month: 02 year: 2016 text: 2016-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer research (Chicago, Ill.) |
| PublicationTitleAlternate | Cancer Res |
| PublicationYear | 2016 |
| References | 9237759 - Nature. 1997 Jul 24;388(6640):394-7 23428224 - Crit Rev Immunol. 2012;32(6):463-88 25871013 - J Innate Immun. 2015;7(5):443-9 20553753 - Dev Comp Immunol. 2010 Sep;34(9):915-25 174433 - Am J Pathol. 1975 Dec;81(3):590-606 10843666 - J Immunol. 2000 Jun 15;164(12):6166-73 2432129 - J Immunol. 1987 Jan 15;138(2):550-65 1401910 - J Immunol. 1992 Oct 15;149(8):2709-14 2538541 - J Exp Med. 1989 Mar 1;169(3):1021-9 4126770 - J Exp Med. 1973 Nov 1;138(5):1213-29 2332635 - J Immunol. 1990 May 15;144(10):3877-80 25492861 - Cancer Res. 2015 Jan 15;75(2):306-15 14194388 - J Exp Med. 1964 Jul 1;120:105-20 25838374 - Science. 2015 Apr 3;348(6230):62-8 25999950 - Front Immunol. 2015 May 05;6:212 4588620 - Science. 1974 Feb 8;183(4124):534-6 25138714 - J Innate Immun. 2014;6(6):716-26 21768675 - Indian J Cancer. 2011 Apr-Jun;48(2):246-51 22927549 - J Exp Med. 2012 Sep 24;209(10):1869-82 830402 - Cancer Res. 1977 Jan;37(1):134-6 25035953 - Immunity. 2014 Jul 17;41(1):49-61 21628329 - J Leukoc Biol. 2011 Sep;90(3):413-24 20467425 - Nat Rev Immunol. 2010 Jun;10(6):453-60 25858805 - Cancer Cell. 2015 Apr 13;27(4):462-72 5014438 - Science. 1972 Apr 14;176(4031):170-1 6189937 - J Exp Med. 1983 May 1;157(5):1448-60 11942557 - Crit Rev Immunol. 2001;21(5):399-425 21436454 - Science. 2011 Mar 25;331(6024):1612-6 Mills (2022061706063039000_bib24) 2015; 7 Mills (2022061706063039000_bib16) 2000; 164 Robert (2022061706063039000_bib22) 2010; 34 Mills (2022061706063039000_bib12) 2015; 6 Todaro (2022061706063039000_bib5) 1975; 81 Cavaillion (2022061706063039000_bib1) 2011; 90 Mills (2022061706063039000_bib6) 2012; 32 Mackaness (2022061706063039000_bib13) 1964; 120 Ruffell (2022061706063039000_bib18) 2015; 13 Albina (2022061706063039000_bib28) 1989; 169 Erhlich (2022061706063039000_bib2) 1957 Prehn (2022061706063039000_bib8) 1972; 176 Mills (2022061706063039000_bib29) 2014; 6 Mills (2022061706063039000_bib4) 1983; 157 Stutman (2022061706063039000_bib7) 1974; 183 Evans (2022061706063039000_bib21) 1977; 37 Mills (2022061706063039000_bib15) 2001; 21 Geissmann (2022061706063039000_bib27) 2010; 10 Rosenberg (2022061706063039000_bib9) 2015; 348 Wang (2022061706063039000_bib23) 2015; 75 Mills (2022061706063039000_bib11) 1992; 149 Beatty (2022061706063039000_bib19) 2011; 331 O'Sullivan (2022061706063039000_bib20) 2012; 209 Albina (2022061706063039000_bib10) 1990; 144 Hibbs (2022061706063039000_bib14) 1987; 138 Noy (2022061706063039000_bib17) 2014; 41 Shevach (2022061706063039000_bib25) 1973; 138 Thomas (2022061706063039000_bib3) 2011; 48 Medzhitov (2022061706063039000_bib26) 1997; 388 |
| References_xml | – volume: 48 start-page: 246 year: 2011 ident: 2022061706063039000_bib3 article-title: The role of innate immunity in the spontaneous regression of cancer publication-title: Int J Cancer contributor: fullname: Thomas – start-page: 550 year: 1957 ident: 2022061706063039000_bib2 article-title: Uber den jetzigen Stand der Karzinomforschung contributor: fullname: Erhlich – volume: 138 start-page: 550 year: 1987 ident: 2022061706063039000_bib14 article-title: L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells publication-title: J Immunol doi: 10.4049/jimmunol.138.2.550 contributor: fullname: Hibbs – volume: 6 start-page: 212 year: 2015 ident: 2022061706063039000_bib12 article-title: Anatomy of a discovery: M1 and M2 macrophages publication-title: Front Immunol doi: 10.3389/fimmu.2015.00212 contributor: fullname: Mills – volume: 149 start-page: 2709 year: 1992 ident: 2022061706063039000_bib11 article-title: Macrophage arginine metabolism and the inhibition or stimulation of cancer publication-title: J Immunol doi: 10.4049/jimmunol.149.8.2709 contributor: fullname: Mills – volume: 21 start-page: 399 year: 2001 ident: 2022061706063039000_bib15 article-title: Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue publication-title: Crit Rev Immunol doi: 10.1615/CritRevImmunol.v21.i5.10 contributor: fullname: Mills – volume: 75 start-page: 306 year: 2015 ident: 2022061706063039000_bib23 article-title: Novel mechanism of macrophage-mediated metastasis revealed in a zebrafish model of tumor development publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-2819 contributor: fullname: Wang – volume: 7 start-page: 443 year: 2015 ident: 2022061706063039000_bib24 article-title: Sequential immune responses: the weapons of immunity publication-title: J Innate Immun doi: 10.1159/000380910 contributor: fullname: Mills – volume: 138 start-page: 1213 year: 1973 ident: 2022061706063039000_bib25 article-title: Function of macrophages in antigen recognition by guinea pig T lymphocytes. II. Role of the macrophage in the regulation of genetic control of the immune response publication-title: J Exp Med doi: 10.1084/jem.138.5.1213 contributor: fullname: Shevach – volume: 348 start-page: 62 year: 2015 ident: 2022061706063039000_bib9 article-title: Adoptive cell transfer as personalized immunotherapy for human cancer publication-title: Science doi: 10.1126/science.aaa4967 contributor: fullname: Rosenberg – volume: 34 start-page: 915 year: 2010 ident: 2022061706063039000_bib22 article-title: Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates publication-title: Dev Comp Immunol doi: 10.1016/j.dci.2010.05.011 contributor: fullname: Robert – volume: 164 start-page: 6166 year: 2000 ident: 2022061706063039000_bib16 article-title: M-1/M-2 macrophages and the Th1/Th2 paradigm publication-title: J Immunol doi: 10.4049/jimmunol.164.12.6166 contributor: fullname: Mills – volume: 81 start-page: 590 year: 1975 ident: 2022061706063039000_bib5 article-title: Parke-Davis Award lecture. Evolution and modes of transmission of RNA tumor viruses publication-title: Am J Pathol contributor: fullname: Todaro – volume: 209 start-page: 1869 year: 2012 ident: 2022061706063039000_bib20 article-title: Cancer immunoediting by the innate immune system in the absence of adaptive immunity publication-title: J Exp Med doi: 10.1084/jem.20112738 contributor: fullname: O'Sullivan – volume: 32 start-page: 463 year: 2012 ident: 2022061706063039000_bib6 article-title: M1 and M2 Macrophages: oracles of health and disease publication-title: Crit Rev Immunol doi: 10.1615/CritRevImmunol.v32.i6.10 contributor: fullname: Mills – volume: 90 start-page: 413 year: 2011 ident: 2022061706063039000_bib1 article-title: The historical milestones in the understanding of leukocyte biology initiated by Elie Metchinikoff publication-title: J Leuk Biol doi: 10.1189/jlb.0211094 contributor: fullname: Cavaillion – volume: 13 start-page: 462 year: 2015 ident: 2022061706063039000_bib18 article-title: Macrophages and therapeutic resistance in cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.02.015 contributor: fullname: Ruffell – volume: 144 start-page: 3877 year: 1990 ident: 2022061706063039000_bib10 article-title: Temporal expression of different pathways of 1-arginine metabolism in healing wounds publication-title: J Immunol doi: 10.4049/jimmunol.144.10.3877 contributor: fullname: Albina – volume: 183 start-page: 534 year: 1974 ident: 2022061706063039000_bib7 article-title: Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice publication-title: Science doi: 10.1126/science.183.4124.534 contributor: fullname: Stutman – volume: 176 start-page: 170 year: 1972 ident: 2022061706063039000_bib8 article-title: The immune reaction as a stimulator of tumor growth publication-title: Science doi: 10.1126/science.176.4031.170 contributor: fullname: Prehn – volume: 120 start-page: 105 year: 1964 ident: 2022061706063039000_bib13 article-title: The immunological basis of acquired cellular resistance publication-title: J Exp Med doi: 10.1084/jem.120.1.105 contributor: fullname: Mackaness – volume: 157 start-page: 1448 year: 1983 ident: 2022061706063039000_bib4 article-title: Expression of passively transferred immunity against an established tumor depends on the generation of cytolytic T cells in the recipient. Inhibition by suppressor T cells publication-title: J Exp Med doi: 10.1084/jem.157.5.1448 contributor: fullname: Mills – volume: 331 start-page: 1612 year: 2011 ident: 2022061706063039000_bib19 article-title: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans publication-title: Science doi: 10.1126/science.1198443 contributor: fullname: Beatty – volume: 169 start-page: 1021 year: 1989 ident: 2022061706063039000_bib28 article-title: Regulation of macrophage functions by L-arginine publication-title: J Exp Med doi: 10.1084/jem.169.3.1021 contributor: fullname: Albina – volume: 41 start-page: 49 year: 2014 ident: 2022061706063039000_bib17 article-title: Tumor-associated macrophages: from mechanisms to therapy publication-title: Immunity doi: 10.1016/j.immuni.2014.06.010 contributor: fullname: Noy – volume: 10 start-page: 453 year: 2010 ident: 2022061706063039000_bib27 article-title: Unravelling mononuclear phagocyte heterogeneity publication-title: Nat Rev Immunol doi: 10.1038/nri2784 contributor: fullname: Geissmann – volume: 6 start-page: 716 year: 2014 ident: 2022061706063039000_bib29 article-title: M1 and M2 Macrophages: the chicken and the egg of immunity publication-title: J Innate Immun doi: 10.1159/000364945 contributor: fullname: Mills – volume: 37 start-page: 134 year: 1977 ident: 2022061706063039000_bib21 article-title: Genetics of colon carcinogenesis in mice treated with 1, 2-dimethylhydrazine publication-title: Cancer Res contributor: fullname: Evans – volume: 388 start-page: 394 year: 1997 ident: 2022061706063039000_bib26 article-title: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity publication-title: Nature doi: 10.1038/41131 contributor: fullname: Medzhitov |
| SSID | ssj0005105 |
| Score | 2.6271987 |
| SecondaryResourceType | review_article |
| Snippet | Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression of... Abstract Successful immunotherapy of cancer is becoming a reality aided by the realization that macrophages play an important role in the growth or regression... |
| SourceID | swepub pubmedcentral proquest crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 513 |
| SubjectTerms | Animals Humans Immunotherapy - methods Macrophages - immunology Medicin och hälsovetenskap Neoplasms - immunology Neoplasms - pathology Neoplasms - therapy |
| Title | A Breakthrough: Macrophage-Directed Cancer Immunotherapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26772756 https://search.proquest.com/docview/1762342451 https://pubmed.ncbi.nlm.nih.gov/PMC4738030 http://kipublications.ki.se/Default.aspx?queryparsed=id:132848498 |
| Volume | 76 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAviG_CAAWJt8llie3Y5gVVA7QB3dMm7c2KE0edVrKpHy_763cXO01CiwQ8JIrs1Knudz7fne_OhHwAFVpbkTrKhcgo51VKdWELyiyshq4sK5_FPz3Njs_59wtxMRp97kUtrVd2XNzuzCv5H1ShDXDFLNl_QHYzKDTAM-ALd0AY7n-F8QSgcflVOGsHjftpjkdyzUBIUC_M0IGLwC4OTjATJORbDfZyQ38o-zNr9nV9gEYjQObzcc9dgLmDy94-fRcx_NPVt22mtZsfdE7tfLHwhQx8FHfwngZPQ7IJTsaFopOOkvv6j6349Me3BDZhPVkofJLptowWygc1Kiq4TMEOr2kiaCJ99Zcebje_GuDSDEwAKX6rmN2swW3XPXI_lVqg9f3l5EcX4wPaY0jbgq9-3PlNLAcdRhnqJlsGx3bc7KC6bKORnD0mj4IpEU88XzwhI1c_JQ-mIVjiGVGTuM8en-IdzBF78OMBczwn59--nh0d03BQBi0ylqyodVY7zmypRWW5ZhVMvgomn9WosGaZ1iDHmeIJvCYyVqZplcpC8pyXgrOKsRdkr76u3SsSV_wwPxRKWsxyK8F8SFjJYSCwKotMZzIi45ZE5sbXQzGNHSkUxjEog-Q1R5NTkwiD5I3I-5aQBiQXbkfltbteL6EXVG_ceE8i8tITdjNki0hE5IDkmxewKvqwp76cNdXRuWQKVq6IpB6c4U9AKzGh_eoSL7N0JmGgpCmu1es__pF98rCbEm_I3mqxdm9BHV3Zdw3L3QFaroS- |
| link.rule.ids | 230,315,786,790,891,27957,27958 |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Breakthrough%3A+Macrophage-Directed+Cancer+Immunotherapy&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Mills%2C+Charles+D&rft.au=Lenz%2C+Laurel+L&rft.au=Harris%2C+Robert+A&rft.date=2016-02-01&rft.eissn=1538-7445&rft.volume=76&rft.issue=3&rft.spage=513&rft_id=info:doi/10.1158%2F0008-5472.can-15-1737&rft_id=info%3Apmid%2F26772756&rft.externalDocID=26772756 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |